Deals
Bambusa Files For Nasdaq IPO With $41.1 Million Loss, No Revenue And A Going-Concern Warning
The Boston antibody developer's S-1 leaves price and share count blank and says $71.5 million in cash may not last a year.
Deals
The Boston antibody developer's S-1 leaves price and share count blank and says $71.5 million in cash may not last a year.
Deals
The second amended filing sets an exchange ratio range, a 12-seat board and a $2.5 billion Treeline value against $460 million for Standard BioTools.
Deals
A KKR-affiliated holder agreed to buy 40 million shares, and underwriters took up their full 12 million-share option on Friday.
Deals
The Parkinson's cell-therapy developer's S-1 reports a $36.5 million six-month loss and leaves the share count and price range blank.
Deals
The Nigeria-focused fintech filed to list ADSs on the NYSE as OPAY; price, share count and offering size are blank.
Deals
Any deal is also expected to need a majority of votes cast by shareholders not held by JBS or its affiliates.
Deals
Canada's banking regulator approved the program, which is also capped at 61 million common shares.
Deals
The pick takes effect only when the all-stock Essential Utilities merger closes, which the companies expect by the end of the first quarter of 2027.
Deals
An amended S-4 shows Slate holders and new investors taking the rest, with a dividend of about $270 million paid before closing.
Deals
The insurer says it has no link to Ocehan LLC and does not endorse the unsolicited mini-tender offer, which targets 100,000 common shares.
Deals
Payoneer's 8-K says Eilam left the board and two committees, and the board is fixed at seven seats ahead of the merger.
Deals
Devon says after-tax proceeds will go to faster share buybacks and debt reduction; the sale covers about 4% of its total oil-equivalent production.